Iovance's cervical cancer TIL trial C-145-04 terminated after meeting event threshold
Iovance Biotherapeutics' Phase 2 study of LN-145 in cervical carcinoma was terminated early with results now posted, after enrolling 210 participants across five cohorts.
This week's update centers on the closeout of a long-running Iovance trial testing its tumor-infiltrating lymphocyte therapy in cervical cancer.
- LN-145 (autologous tumor infiltrating lymphocytes), Phase 2, recurrent, metastatic or persistent cervical carcinoma (NCT03108495): the trial's status is now listed as terminated, with the sponsor stating that Iovance concluded the study reached the required number of events for evaluation of study endpoints.1 The study had five cohorts testing LN-145 monotherapy or in combination with pembrolizumab1, enrolled 210 participants (actual)1, and had results first posted on 2026-07-31.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.